Company: PGEN
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001356090-25-000007
Chunk: 323

Company: PRECIGEN, INC.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 16
Chunk 323
---
 less than the stock's fair market value at the date of grant only if the stock options are replacement options in accordance with certain United States Treasury regulations. All stock options have terms of up to ten-year and vest four years from the date of grant.Stock option activity was as follows:Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Balances at December 31, 202112,260,187 $14.06 6.79Granted4,451,890 2.22 Exercised(375)(2.28)Forfeited(567,179)(5.19)Expired(943,247)(22.32)Balances at December 31, 202215,201,276 10.41 6.87Granted7,847,869 1.19 Exercised— — Forfeited(275,250)(2.65)Expired(716,555)(20.41)Balances at December 31, 202322,057,340 6.90 7.12Granted7,361,674 1.40 Exercised(265,448)(1.30)Forfeited(1,586,732)(1.72)Expired(1,642,100)(17.10)Balances at December 31, 202425,924,734 5.07 7.05Exercisable at December 31, 202415,384,119 7.42 5.89Total unrecognized compensation costs related to unvested awards as of December 31, 2024 were $10,135 and are expected to be recognized over a weighted-average period of approximately 2.5 years.The weighted average grant date fair value of options granted during 2024, 2023, and 2022 was $1.12, $0.92, and $1.65, respectively. The aggregate intrinsic value of options exercised during 2024, 2023, and 2022 was $60, $0, and $0, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Precigen's common stock for those shares where the exercise price was lower than the fair value of Precigen's common stock on the date of exercise.

F-39

PSUs and RSUsIn 2024, the Company’s Compensation and Human Capital Management Committee